🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Sema fatigue at month 6 — caloric deficit mitigation strategies

Sema fatigue at month 6 — caloric deficit mitigation strategies

Dr.NutriCornell Wed, May 6, 2026 at 8:51 AM 6 replies 473 viewsPage 1 of 2
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
May 6, 2026 at 8:51 AM#1

Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about fatigue, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

Mostly the deficit, and the useful part of that answer is that it is testable. Fatigue driven by a deficit tracks intake, improves within a day or two of eating properly, and worsens on the days you eat least. Fatigue that is flat regardless of intake, or that arrives on a fixed day after dosing, is behaving like a drug effect. Before assuming either, rule out the boring causes — iron, B12, thyroid, and sleep — because a fast deficit unmasks deficiencies that were previously subclinical.

The condition it depends on

The commonest reversible cause in practice is inadequate protein plus inadequate sodium, not iron. People restrict salt at the same time as calories without noticing.

The practical version

Worth checking before concluding it is the drug: ferritin, B12, TSH, and total intake for three honest days. Two of those four explain most cases.

What I am not sure about

What I am after is whether the fatigue is a direct drug effect or simply the caloric deficit, because the answer changes what you do about it. Practical detail welcome, however dull — the duller the better.

— Dr.NutriCornell · corrections welcome and will be edited into this post with credit
25 20emily_PDX, Dr.SleepRoch, laura_annarbor and 22 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
May 6, 2026 at 9:12 AM#2
Dr.NutriCornell said:
Mostly the deficit, and the useful part of that answer is that it is testable.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

24 19PharmHunterJen, TomTeleRx, DoseLogDan and 21 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
May 6, 2026 at 9:33 AM#3
Dr.NutriCornell said:
Mostly the deficit, and the useful part of that answer is that it is testable.

This is where I part company with the consensus forming above. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.

Last edited: May 6, 2026 at 2:33 PM
23 18maya_sedona, stefan_berlin, Dr.EM_Chicago and 20 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
May 6, 2026 at 9:54 AM#4

This one has a reasonably settled answer, so here it is. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Last edited: May 6, 2026 at 3:54 PM
22 17stefan_berlin, Dr.EM_Chicago, pete_RVA and 19 others
Reply Quote Save Share Report
DadBodDave
Member
187
923
Nov 2024
Ohio
May 6, 2026 at 11:49 AM#5
TrialNerd_Beth said:
Whether it is right for the case being asked about depends on a detail that has not been given.

Can confirm. Same sequence, different timescale. I had assumed I was the exception until I read this.

21 16JakeBK_lifts, DerekSJ_a1c, paige_pharma and 18 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register